This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Adam Feuerstein

Senior Columnist

Before joining TheStreet in March 2001, Feuerstein covered business software for Upside.com. Prior to that he covered a variety of business beats, including technology and commercial real estate, at the San Francisco Business Times.


Feuerstein graduated from Emory University with a bachelor's degree in political science.


Adam Feuerstein
By This Author:
Page 2 of 570

Keryx Bear Case Bolstered by Less-Than-Zippy 'Zerenex' Label

By Adam Feuerstein

Missing anemia benefit from "Zerenex" label makes Keryx's phosphate binder a tough sell.

07:00AM 09/08/14

Biotech Stock Mailbag: Achillion, Ariad Revisited, Endocyte

By Adam Feuerstein

Biotech columnist Adam Feuerstein answers readers' questions about health care.

08:55AM 09/05/14

Merck Skin Cancer Immunotherapy Gets FDA Approval

By Adam Feuerstein

Merck will sell the skin cancer drug under the brand name Keytruda.

02:36PM 09/04/14

Google Healthcare Startup Calico Partners With Abbvie

By Adam Feuerstein

Under the agreement, Calico and Abbvie will work together to discover and develop new drugs for age-related diseases, including neuro-degeneration and cancer.

01:19PM 09/03/14

Simple Math Shows Ampio Knee Arthritis Drug is No Better Than Saline

By Adam Feuerstein

With Ampion failure, Ampio's pipeline is worthless.

12:04PM 09/03/14

Infinity Pharma Snags Abbvie for Blood Cancer Drug Partnership

By Adam Feuerstein

Infinity and Abbvie will jointly develop and market duvelisib.

06:57AM 09/03/14

Sunesis Takes a Run Through the Feuerstein-Ratain Rule

By Adam Feuerstein

Results from Sunesis' phase III study in acute myeloid leukemia should be released this month or next.

10:29AM 09/02/14

Exelixis Drug Fails Pivotal Prostate Cancer Study

By Adam Feuerstein

As a result of the negative prostate cancer study, Exelixis intends to downsize by firing 70% of its workforce.

09:33AM 09/02/14

Your September Biotech Back-to-School Calendar

By Adam Feuerstein

The biotech sector hews close to an academic calendar and September marks the start of the busy, event-filled push into the end of the year.

09:50AM 08/26/14

Biotech Stock Boom Times Are Back

By Adam Feuerstein

The iShares Nasdaq Biotechnology ETF closed at 272.63 Monday, less than one point below the year (and all-time) closing high reached on Feb. 25.

07:00AM 08/26/14

Page 2 of 570

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs